ASH: Novartis Looks To Challenge Frontline DLBCL Standard Of Care With Next-Gen CAR-T

The Swiss drug maker presented Phase II data at ASH for rapcabtagene autoleucel, also called YTB323, showing a 65% CR rate in relapsed/refractory diffuse large B-cell lymphoma.